Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement issued Tuesday.
The company said it was shutting a program focused on heart failure and outlined reset priorities for other programs. The layoffs will be complete by the end of the year, according to an SEC filing.
Between 75 to 80 employees are affected, Sana’s vice president of finance Nicole Keith told GeekWire. The company has operations in Seattle, South San Francisco and Cambridge, Mass.
